The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., Berthold, D., Ronchin, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00367-1 · Cited by 847
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 833
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01638 · Cited by 736
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
Self-citationThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5801 · Cited by 667
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., Kramer, G., Eymard, J.-C., Bamias, A., Carles, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911206 · Cited by 663
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., Jain, S., Varughese, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 634
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Polkinghorn, W. R., Parker, J. S., Lee, M. X., Kass, E. M., Spratt, D. E., Iaquinta, P. J., Arora, V. K., Yen, W.-F., Cai, L., Zheng, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0172 · Cited by 559
Self-citationAbida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Chi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez, A., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03488 · Cited by 525
Small, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Sartor, O., Coleman, R., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70183-4 · Cited by 497
Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Jemal, A., Fedewa, S. A., Ma, J., Siegel, R., Lin, C. C., Brawley, O., & Ward, E. M. (2015) · JAMA · doi:10.1001/jama.2015.14905 · Cited by 469
Gravis, G., Boher, J.-M., Joly, F., Soulié, M., Albiges, L., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.005 · Cited by 459
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Self-citationDual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003892 · Cited by 428
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200043 · Cited by 426
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30860-x · Cited by 413
Hoskin, P., Sartor, O., O'Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J., Bottomley, D., Nilsson, S., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 407
Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 396
Abida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0394 · Cited by 383
Self-citationCastro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00358 · Cited by 377
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001342 · Cited by 368
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., Wallmark, J. M., Keam, B., Delord, J.-P., Aggarwal, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy232 · Cited by 363
Khalaf, D. J., Annala, M., Taavitsainen, S., Finch, D. L., Oja, C., Vergidis, J., Zulfiqar, M., Sunderland, K., Azad, A. A., Kollmannsberger, C. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30688-6 · Cited by 360
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 359
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 357
Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01649 · Cited by 355
Self-citationNoonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343
Self-citationEnzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, A. J., Azad, A. A., Iguchi, T., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Alcaraz, A., Alekseev, B., Shore, N. D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00193 · Cited by 316
Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 295
Apalutamide and Overall Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.08.011 · Cited by 290
de Bono, J. S., Mehra, N., Scagliotti, G. V., Castro, E., Dorff, T., Stirling, A., Stenzl, A., Fleming, M. T., Higano, C. S., Saad, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00376-4 · Cited by 286
Self-citationLogothetis, C. J., Basch, E., Molina, A., Fizazi, K., North, S. A., Chi, K. N., Jones, R. J., Goodman, O. B., Mainwaring, P. N., Sternberg, C. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70473-4 · Cited by 280
Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Cheng, H. H., Pritchard, C. C., Boyd, T., Nelson, P. S., & Montgomery, B. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 261
Self-citationSmith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., Hauke, R. J., Monk, J. P., Saylor, P., Bhoopalam, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.6500 · Cited by 251
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Beltran, H., Tagawa, S. T., Park, K., MacDonald, T., Milowsky, M. I., Mosquera, J. M., Rubin, M. A., & Nanus, D. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5166 · Cited by 229
Ryan, C. J., Shah, S., Efstathiou, E., Smith, M. R., Taplin, M.-E., Bubley, G. J., Logothetis, C. J., Kheoh, T., Kilian, C., Haqq, C. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0815 · Cited by 219
Chi, K. N., Sandhu, S., Smith, M. R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A. J., Small, E. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.009 · Cited by 217
Kellokumpu-Lehtinen, P.-L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70537-5 · Cited by 212
Corn, P. G., Heath, E. I., Zurita, A., Ramesh, N., Xiao, L., Sei, E., Li-Ning-Tapia, E., Tu, S.-M., Subudhi, S. K., Wang, J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30408-5 · Cited by 210
Fizazi, K., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D., Forer, D., Hirmand, M., & de Bono, J. S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70303-1 · Cited by 208
Bianchini, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S., & de Bono, J. S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.020 · Cited by 204
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., Chowdhury, S., Frydenberg, M., Horvath, L. G., Joshua, A. M., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00063-3 · Cited by 204
Drazer, M. W., Huo, D., & Eggener, S. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6532 · Cited by 194
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., & Parker, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 182
Szmulewitz, R. Z., Peer, C. J., Ibraheem, A., Martinez, E., Kozloff, M. F., Carthon, B., Harvey, R. D., Fishkin, P., Yong, W. P., Chiong, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4381 · Cited by 182
Antonarakis, E. S., Lu, C., Luber, B., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 179
Avascular necrosis of the jaws: risk factors in metastatic cancer patients
Tarassoff, P., & Csermak, K. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2003.09.001 · Cited by 175
Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt194 · Cited by 163
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
Mota, J. M., Barnett, E. S., Nauseef, J. T., Nguyen, B., Stopsack, K. H., Wibmer, A. G., Flynn, J. R., Heller, G., Danila, D. C., Rathkopf, D. E., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00346 · Cited by 161
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 154
Denmeade, S. R., Wang, H., Agarwal, N., Smith, D. C., Schweizer, M. T., Stein, M. N., Assikis, V. J., Twardowski, P. W., Flaig, T. W., Szmulewitz, R. Z., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02759 · Cited by 144
Dupont, A., Gomez, J., Cusan, L., Koutsilieris, M., & Labrie, F. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)35646-x · Cited by 133
Fred Saad, C., Cella, D. F., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S. M., Graff, J. N., McQuarrie, K., Li, S., Hudgens, S. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30456-x · Cited by 133
Abida, W. M., Campbell, D. C., Patnaik, A., Bryce, A. H., Shapiro, J. D., Bambury, R. M., Zhang, J., Burke, J. M., Castellano, D., Pous, A. F., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.05.021 · Cited by 128
Self-citationMateo, J., Cheng, H. H., Beltran, H., Dolling, D. I., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Pérez-López, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 127
Self-citationBarocas, D. A., Mallin, K., Graves, A. J., Penson, D. F., Palis, B. E., Winchester, D. P., & Chang, S. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.075 · Cited by 126
Self-citationSchmid, S., Omlin, A. G., Higano, C. S., Sweeney, C. J., Chanzá, N. M., Mehra, N., Kuppen, M. C. P., Beltran, H., Conteduca, V., de Almeida, D. V. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21692 · Cited by 122
Agarwal, N., McQuarrie, K., Bjartell, A. S., Chowdhury, S., Gomes, A. J., Chung, B. H., Özgüroğlu, M., Soto, Á. J., Merseburger, A. S., Uemura, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30620-5 · Cited by 120
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 109
Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 104
Leapman, M., Wang, R., Park, H., Yu, J. B., Sprenkle, P. C., Cooperberg, M. R., Gross, C. P., & Ma, X. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5143 · Cited by 90
Loriot, Y., Massard, C., Gross‐Goupil, M., Palma, M. D., Escudier, B. J., Bossi, A., & Fizazi, K. S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn694 · Cited by 85
Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Tucker, M. D., Zhu, J., Marin, D., Gupta, R. T., Gupta, S. K., Berry, W. R., Ramalingam, S., Zhang, T., Harrison, M. R., Wu, Y. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2375 · Cited by 84
Self-citationMeisel, A., von Felten, S., Vogt, D., Liewen, H., de Wit, R., Bono, J. S. D., Sartor, O. A., & Stenner, F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.009 · Cited by 80
Higano, C. S., Armstrong, A. J., Sartor, O. A., Vogelzang, N. J., Kantoff, P. W., McLeod, D. G., Pieczonka, C. M., Penson, D. F., Shore, N. D., Vacirca, J. L., et al. (2019) · Cancer · doi:10.1002/cncr.32445 · Cited by 80
Kearns, J. T., Holt, S. K., Wright, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31337 · Cited by 74
Fizazi, K. S., Kramer, G., Eymard, J., Sternberg, C. N., Bono, J. S. D., Castellano, D., TOMBAL, B. F., Wülfing, C., Liontos, M., Carles, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30449-6 · Cited by 64
Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.022 · Cited by 63
Fedewa, S. A., Ward, E., Brawley, O. W., & Jemal, A. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.0340 · Cited by 55
Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F. X., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.6_suppl.lba16 · Cited by 55
Shamash, J., Powles, T. B., Sarker, S., Protheroe, A., Mithal, N., Mills, R., Beard, R., Wilson, P., Tranter, N., O’Brien, N., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.7 · Cited by 51
Nakabayashi, M., Sartor, O. A., Jacobus, S. J., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07331.x · Cited by 45
Romero-Laorden, N., Lozano, R., Jayaram, A., López‐Campos, F., Sáez, M. I., Montesa, Á., Gutiérrez-Pecharromán, A., Villatoro, R., Herrera‐Imbroda, B., Correa, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0123-9 · Cited by 45
Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Bono, J. S. D., Small, E. J., Shore, N. D., Fizazi, K. S., Kheoh, T. S., Li, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.007 · Cited by 43
Ladoire, S., Eymard, J., Zanetta, S., Mignot, G., Martin, E., Kermarrec, I., Mourey, E., Michel, F., Cormier, L., & Ghiringhelli, F. (2010) · PubMed · Cited by 41
Gillessen, S., Choudhury, A., Rodríguez‐Vida, A., Nolè, F., Gallardo, E., Roumeguere, T. A., Daugaard, G., Loriot, Y., Fred Saad, C., McDermott, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.5002 · Cited by 36
Cabrespine, A., Guy, L., Khenifar, E., Curé, H., Fleury, J., Penault-Llorca, F. M., Kwiatkowski, F., Barthomeuf, C., Chollet, P. J. M., & Bay, J. (2006) · Urology · doi:10.1016/j.urology.2005.08.046 · Cited by 30
Lee, J.-L., Ahn, J.-H., Choi, M. K., Kim, Y., Hong, S.-W., Lee, K.-H., Jeong, I.-G., Song, C., Hong, B.-S., Hong, J. H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.204 · Cited by 23
Stein, C. A., Levin, R., Given, R. W., Higano, C. S., Nemeth, P. R., Bosch, B., Chapas-Reed, J., & Dreicer, R. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.10.018 · Cited by 21
Hussaini, A., Olszanski, A. J., Stein, C. A., Bosch, B., & Nemeth, P. R. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3360-3 · Cited by 7
Cited by
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Metadata
- Authors
- Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Guzzo, T., Ippolito, J. E., Kuettel, M. R., Lang, J. M., Lotan, T., McKay, R. R., Morgan, T., Netto, G., Pow-Sang, J. M., Reiter, R., Roach, M., Robin, T., Rosenfeld, S., Shabsigh, A., Spratt, D., Teply, B. A., Tward, J., Valicenti, R., Wong, J. K., Shead, D. A., Snedeker, J., & Freedman-Cass, D. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2023-10
- Volume
- 21
- Issue
- 10
- Pages
- 1067-1096
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4387581619
- Cited by
- 596
- References
- 135
- FWCI
- 94.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.